title: Avoiding infusion therapy prime benefit of new MS drug.
authors.affiliation: Genentech Inc, USA. TMorrow@ManagedCareMag.com
authors.forename: Thomas
authors.initials: T
authors.lastname: Morrow
mesh_terms: D000328:Adult; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007263:Infusions, Parenteral / Q000009:adverse effects; D008329:Managed Care Programs; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine